Compare Merck & Co., Inc. (MRK) vs NextEra Energy, Inc. (NEE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs NextEra Energy, Inc. — how do they compare? Merck & Co., Inc. trades at $148.23 (market cap $366.28B), while NextEra Energy, Inc. trades at $83.15 (market cap $174.87B). The key difference: Merck & Co., Inc. is far larger — about 2.1× NextEra Energy, Inc.'s market cap, and NextEra Energy, Inc. pays the higher dividend (2.97%). Which is the better fit depends on your goals.
| MRK | NEE | |
|---|---|---|
Market Cap | $366.28B | $174.87B |
Sector | Health | Utilities |
52-Week High | $156.43 | $97.88 |
52-Week Low | $77.60 | $69.83 |
Enterprise Value | $413.04B | $282.20B |
Dividend Yield | 2.29% | 2.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
NextEra Energy (NEE) trades at $83.83, showing modest daily gains of 0.48% amid a bearish technical outlook. The company demonstrates strong fundamentals with $27.4B revenue and 32.4% net margins in 2025, though recent Q4 2025 earnings missed expectations. Positive developments include securing a $1.9B DOE loan for nuclear plant restart and ongoing investor meetings. Analyst consensus remains strongly bullish with a $100.20 price target, representing 20% upside potential from current levels.
NEE presents a compelling long-term investment case with robust profitability and strategic growth initiatives in renewable energy and nuclear power. However, investors face risks from rising debt levels (47.6% debt-to-asset ratio) and recent technical weakness. The stock's current discount to analyst targets offers opportunity, but requires monitoring of execution on growth projects and debt management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →
